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We hereby provide the initial portrait of lincNORS, a spliced lincRNA generated by the
MIR193BHG locus, entirely distinct from the previously described miR-193b-365a tandem.
While inducible by low O2 in a variety of cells and associated with hypoxia in vivo, our studies
show that lincNORS is subject to multiple regulatory inputs, including estrogen signals. Bio-
chemically, this lincRNA fine-tunes cellular sterol/steroid biosynthesis by repressing the
expression of multiple pathway components. Mechanistically, the function of lincNORS
requires the presence of RALY, an RNA-binding protein recently found to be implicated in
cholesterol homeostasis. We also noticed the proximity between this locus and naturally
occurring genetic variations highly significant for sterol/steroid-related phenotypes, in par-
ticular the age of sexual maturation. An integrative analysis of these variants provided a more
formal link between these phenotypes and lincNORS, further strengthening the case for its
biological relevance.
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Cells monitor intracellular oxygen (O2) tension using spe-cific dioxygenase enzymes that act as negative regulatorsfor hypoxia-inducible factors (HIF) and their downstream
transcriptional programs1,2. Although the core of this mechanism
is known to operate in essentially all metazoans, decreased O2
(hypoxia) also elicits context-specific responses, which remain
incompletely understood. Similar to other signaling pathways,
valuable insights to this end continue to emerge from noncoding
transcriptome studies3. During the past decade, various types of
non-coding RNAs have been shown to respond to hypoxia,
potentially functioning as feedback elements that impact various
branches of this response. Among the best documented is miR-
210, the prototypical hypoxia microRNA4 thought to fine-tune
mitochondrial activity to environmental O2 availability5. More
recently, the oxygen-sensitive noncoding transcriptome has been
expanded to include hypoxia-inducible lncRNAs, such as NEAT1,
MALAT1, MEG3, H19, NLUCAT1, HOTAIR, HIF-1-AS2, and
MIR210HG6–11. Although these lncRNAs exert biochemical and
phenotypical effects during experimental oxygen deprivation,
there is extensive evidence to support their involvement in a
broader spectrum of responses12. Furthermore, their overall
relevance in physiology and disease remains insufficiently
understood.
Here we present an initial analysis of the mature lincRNA
product of MIR193BHG locus, henceforth termed Noncoding
Oxygen-Sensitive Regulator of Sterol Homeostasis (lincNORS).
This locus was previously investigated exclusively in the context
of the miR-193b-365a tandem. Our investigation reveals a con-
nection between lincNORS, oxygen-sensing, and steroid hormone
responses, adding to the growing evidence of the interdependence
and overlap between these networks13. Our study identifies a
previously unrecognized modulator of the cellular steroid bio-
synthesis pathways and points to its relevance for specific human
phenotypes.
Results
Identification and characterization of lincNORS. We first
screened noncoding transcripts induced by decreased O2 ten-
sion in MCF7 breast cancer cells. RNA-seq analysis captured
the expected hypoxic coding signature and the increased
abundance of NEAT1, MALAT1, MIR210HG, and HIF1A-AS2,
known as non-coding hypoxic transcripts (Fig. 1a, Supple-
mentary Fig. 1a, and Supplementary Data 1)6–9. Among the top
upregulated noncoding RNAs, we identified a previously
uncharacterized lncRNA, ENSG00000262454/RP11-65J21.3/
MIR193BHG, corresponding to the genomic locus that hosts
the miR193b-365a tandem (Supplementary Fig. 1b). The miR-
193b and miR-365a sequences are intronic to this locus and
are therefore lost during splicing, justifying a specific desig-
nation for the mature lncRNA. Our decision to focus on this
transcript was due to its consistent and wide-range response to
oxygen deprivation in a broad spectrum of human cell lines,
both transformed and non-transformed (Fig. 1b, c and Sup-
plementary Fig. 1c). Although early studies were performed
under severe hypoxia (0.2% O2), predominantly encountered
in the tumor environment, subsequent studies were
performed under 1–2% O2, an in vitro approximation of
physiologically low O23,14. Interestingly, no significant induc-
tion of miR-193b and miR-365a was observed upon O2 depri-
vation, in contrast to miR-210, which exhibited the expected
induction (Fig. 1d). The result reflects published microRNA-
seq and RNA-seq data for MCF-7 cells, whereas these miRNAs
are rarely reported as hypoxia-inducible15–17. A potential
explanation is that miRNA biogenesis is partially impaired
during hypoxia18,19.
Analysis of The Cancer Genome Atlas (TCGA) data sets
revealed a positive correlation between lincNORS expression and
a panel of well-established hypoxia signature genes in several
cancers, including triple-negative breast cancer (TNBC) and
pancreatic adenocarcinoma (PAAD) (Fig. 1e and Supplementary
Data 2). Using a hypoxia score, calculated based on the hypoxia
metagenes established by Buffa et al.20, we further showed that in
both TNBC and PAAD, the in vivo lincNORS levels were more
closely associated with the hypoxia state than NEAT1, a lncRNA
known to respond to oxygen deprivation (Supplementary
Fig. 1d).
To begin characterization of this lncRNA, we used 5′-RNA
ligation-mediated rapid amplification of cDNA ends (5′-RACE)
which identified two main transcription start sites (TSS),
corresponding to ENST00000570945/MIR193BHG-001 and
ENST00000634265/MIR193BHG-004, matching cap analysis of
gene expression (CAGE) information from the FANTOM project
(Supplementary Fig. 2a, b)21. Furthermore, the two polyadenyla-
tion (PolyA) sites identified by 3′ RACE agree with Cancer
Genome PolyA Site & Usage data (Supplementary Fig. 2a, b). A
closer examination of lincNORS revealed well-recognized features
of a bona fide lncRNA. First, multiple coding-potential analyses
produced consistently low scores (Supplementary Fig. 2c), and
the SORFS mass spectrometry database (http://sorfs.org/
database) did not list any peptides associated with this locus at
the time of writing. Second, the locus is separated from the
flanking ones. Third, as expected for a lncRNA, lincNORS is
expressed in a tissue-specific pattern, with a higher abundance in
hormone-responsive tissues and skeletal muscle (Supplementary
Fig. 3). Furthermore, GTEx data sets indicate an overall
abundance comparable to, or higher than, the well-established
lncRNAs HOTAIR, CCAT1, and MIR210HG (Supplementary
Fig. 3).
Cell fractionation revealed a predominant, albeit not exclusive,
nuclear localization of lincNORS in MCF7 cells (Fig. 1f).
Furthermore, the majority of nuclear lincNORS is chromatin-
associated, a relatively common feature of lncRNAs involved in
gene expression regulation. Individual lincNORS loci were
visualized by hybridization with custom-designed RNAscope®
probes, a pattern consistent with nuclear enrichment and hypoxic
responsiveness (Supplementary Fig. 1e).
Upstream molecular determinants of lincNORS abundance. To
gain deeper insights into the hypoxic induction of lincNORS, we
profiled the response at the primary transcript level using the
nascent RNA Bru-seq method (Supplementary Data 3)22. As
shown in Fig. 2a, the MIR193BHG locus exhibited a significantly
increased signal in hypoxic cells, consistent with a transcriptional
effect. As internal controls for the assay, canonical hypoxia-
inducible genes displayed the expected activation (Supplementary
Fig. S4a).
Based on the evidence for a transcriptional response at this
locus, we further tested the possible role of HIF-α isoforms in
loss-of-function experiments. Although HIF-1α depletion had no
measurable effect on lincNORS levels (Supplementary Fig. 4b),
HIF-2α knockdown blunted the hypoxic accumulation of
lincNORS in breast cancer cells (Fig. 2b). Supporting evidence
for the role of HIF-2 was obtained using 786-O kidney cancer
cells, which are documented to overexpress HIF-2α and
corresponding targets regardless of O2 tension due to pVHL E3
ligase inactivation1. Similarly, the sensitivity of lincNORS to low
O2 is compromised in VHL-deficient cells and rescued by
restoring VHL expression (Fig. 2c). This result is consistent with
results reported by Zhang et al. listing MIR193BHG (lincNORS)
among the HIF-2 targets23. The preferential role of HIF-2 has
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Fig. 1 lincNORS is an oxygen-regulated, nucleus-located lncRNA. a Heatmap depicting the expression of 47 lincRNAs significantly upregulated (fold
change≥ 2 or≤ 0.5) in MCF-7 cells under hypoxia (1% O2, 24 h) versus normoxia (21% O2, 24 h). Color intensity represents RPKM scaled by the row.
Gene symbol of previously reported hypoxia-inducible lincRNAs and lincNORS was added next to the Ensembl ID. b Validation of lincNORS induction by
hypoxia across diverse cell types, including both tumor (0.2% O2) and non-tumorigenic cell lines (1% O2), and fallopian tube epithelial cells (2% O2).
lincNORS RNA level was measured by qPCR. All the samples were cultured in hypoxia for 24 h except FTE cells (48 h). Data represent mean ± SD from
three biological replicates (**p < 0.01, *p < 0.05, two-sided Student’s t-test). c qPCR analysis of lincNORS expression under 0.2%, 1%, 2% O2 in MCF-7 and
MDA-MB-231 cell lines. Data represent mean ± SD from three biological replicates (**p < 0.01, *p < 0.05, two-sided Student’s t-test). d qPCR analysis of
miR193b, miR365a, miR210, and lincNORS expression in MCF-7 cells cultured under 21% or 1% O2. A diagram of lincNORS and its intronic miRNAs is shown
above. miR210 served as a positive reference for hypoxia-induced miRNA. Data represent mean ± SD from three biological replicates (**p < 0.01, two-sided
Student’s t-test). e Spearman’s correlation between lincNORS and well-established hypoxia signature genes in triple-negative breast cancer (TNBC),
pancreatic adenocarcinoma (PAAD), glioblastoma (GBM), and lung adenocarcinoma (LUAD) from TCGA. The size of the dots is correlated with the
strength of the Spearman’s coefficient. The red color represents a positive correlation while the blue color represents a negative correlation. The
corresponding scale is presented next to the image. “NS” was added inside the dots where the correlation is not significant. The significance is defined as
p < 0.05. f MCF-7 cells were harvested and fractionized after 24 h culture in 21% O2 or 1% O2. The RNA distribution of lincNORS, NEAT1, and GAPDH in
cytoplasmic (CYT), nucleoplasm (NUC), and chromatin-associated (CHR) fractions were assessed by qPCR. NEAT1 and GAPDH were included as nuclear
and cytoplasmic controls. Data represent mean ± SD from three biological replicates. Western blot was performed to confirm cell fractions and a
representative image from three independent experiments was shown.
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been previously described for hypoxia lncRNAs, in particular
NEAT1, MALAT1, and NLUCAT16,11.
A survey of the genomic region surrounding lincNORS using
available ChIP-seq data sets (GSE28352) did not reveal functional
HIF recruitment sites within the lincNORS proximal regulatory
region, in contrast to standard hypoxia responders typically
driven by HIF-1 from proximal promoters (e.g., CA9 and
miR210/MIR210HG) (Fig. 2d)24. Based on the knowledge that
HIFs (and in particular HIF-2) sometimes transactivate from
distant enhancers, we identified major peaks at the neighboring
locus LINC02130 (Fig. 2e and Supplementary Fig. 5a)24,25. This
locus is a plausible distal regulatory element based on (1)
ENCODE genome segmentation features (Supplementary Fig. 5b);
(2) chromatin interaction with the lincNORS proximal regulatory
region (RNAPII ChIA-PET GSE33664) (Fig. 2e)26; (3)
LINC02130 transcript is much less abundant than lincNORS in
tissues and cell lines (Fig. 2e—GTEx track summary and
Supplementary Fig. 1b for MCF7 cells); and (4) evidence of
activation by hypoxia but the corresponding transcript has very
low abundance (Supplementary Fig. 1b). Interestingly, the HIF
prolyl-hydroxylase inhibitor DMOG was much less effective in
inducing lincNORS than low O2 (Supplementary Fig. S4c, d).
Despite inducing the expected hypoxic responses (increased HIF-
2 protein abundance; CA9 transcript upregulation), DMOG
impact on lincNORS was modest in MDA-MB-231 and
reproducibly absent in MCF7. In conclusion, while these data
indicate that lincNORS is a hypoxia-inducible gene, they also
show that it is an atypical one, prompting us to investigate
additional details on lincNORS upregulation.
Detailed examination of the lincNORS genomic neighborhood
revealed hormonal response hallmarks, including DNase I
hypersensitivity peaks that are further stimulated by estradiol
(E2) treatment (Supplementary Fig. 6a), as well as ChIP-seq peaks
for estrogen receptor (ER), ER pioneer factors (FOXA1, GATA3)
and ER coactivators (NCOA3/SRC3) in relevant cell types
(Supplementary Fig. 6b). As is often the case for estrogen-
responsive genes, the major regional ER peak resides at the
putative LINC02130 enhancer (Supplementary Fig. S6a)27.
Accordingly, a mega trans ER enhancer was identified at this
site in the recent study by Rosenfeld and colleagues (Supple-
mentary Fig. 6c)28. Finally, our analysis of TCGA RNA-seq data
sets detected significantly higher lincNORS expression in ER/
progesterone receptor (PR) positive breast tumors compared to
their negative counterparts (Fig. 3a). Collectively, this informa-
tion prompted us to directly test the response of lincNORS to E2
treatment. In short-term experiments, hormonal treatment
resulted in reproducible (if not marked) lincNORS induction
(Fig. 3b). More strikingly, lincNORS expression was dramatically
reduced in long-term estrogen deprivation (LTED) of MCF7 cells
(Fig. 3c).
ChIP-seq data sets also suggest a potential role of FOSL2 in the
regulation of lincNORS, a hypoxia-inducible AP-1 family member
(Supplementary Fig. 5a)29. Using a loss-of-function approach, we
confirmed the positive impact of FOSL2 on lincNORS expression
in breast cancer cells (Supplementary Fig. 5c), predominantly at a
lower oxygen concentration. Based on the evidence that FOSL2
responds to multiple stimuli, including steroid hormones, its role
in the regulation of lincNORS may not be limited to oxygen-
related responses30,31.
lincNORS coordinately modulates the sterol biosynthesis pro-
gram. To gain insight into lincNORS biochemical functions, we
downregulated it using a combination of siRNA/shRNA, similarly
to the recently published studies on the lncRNAs CHROME and
SCAT (Supplementary Fig. 7a)32,33. For transient interventions,
we first validated non-overlapping siRNAs targeting the major
exon of lincNORS (present in all isoforms). Based on their dif-
ferential ability to knockdown lincNORS expression, these will be
henceforth referred to as siNORS_s (strong) and siNORS_w
(weak) (Supplementary Fig. 7b).
We next performed RNA-seq analysis in hypoxic MCF7 cells
to determine the consequences of lincNORS downregulation
(Supplementary Fig. 8a and Supplementary Data 4). Differentially
regulated transcripts were subjected to Gene Set Enrichment
Analysis (GSEA) and Ingenuity Pathway Analysis (IPA), both of
which identified the upregulation of cholesterol biosynthesis as
the top transcriptomic signature (Fig. 4a and Supplementary
Fig. 8b). As illustrated in Fig. 4b and Supplementary Fig. 8c, the
program responsible for the de novo synthesis of cholesterol and
related steroids was coordinately upregulated by lincNORS
siRNA, with significant upregulation of many individual genes.
A similar effect was evidenced in ER-negative MDA-MB-468 cells
using the AmpliSeq platform (Fig. 4c, d and Supplementary
Data 5). Individual genes were validated by qPCR in a diverse cell
panel (Fig. 4e, f and Supplementary Fig. 8d). The impact of
lincNORS may extend beyond biosynthesis, with negative
effects on the STARD4 transport regulator and potentially
other steroid network components (Fig. 4g and Supplementary
Fig. 8f). Similar effects (Fig. 4g) were demonstrated on SCD
(stearoyl CoA desaturase), a gene often coregulated with a sterol
biosynthesis program. Evidence that lincNORS was successfully
repressed came from several lines of evidence: (1) The knock-
down efficiency of siNORS_s was greater than that of siNORS_w
and overall it exhibited a stronger impact on sterol biosynthesis
transcripts; (2) Although this response is also detectable under
high O2, it was generally more obvious at lower oxygenation, as
expected based on lincNORS abundance; (3) lincNORS down-
regulation with a non-overlapping shRNA elicited similar effects
on sterol biosynthesis genes (Supplementary Fig. 8d).
We then performed gain-of-function studies and we stably
expressed full-length lincNORS (NORS_OE) or vector-only
control and performed RNA-seq on cells growing under ambient
O2 (Supplementary Fig. 9a and Supplementary Data 6). Both
GSEA and IPA identified cholesterol biosynthesis among the top
suppressed signatures (Supplementary Fig. 9b, c), with multiple
components downregulated (Supplementary Fig. 9d). We con-
firmed by qPCR the downregulation of MSMO1, SQLE, and
HMGCR as a result of lincNORS transcript induction (Supple-
mentary Fig. 9e). As expected, this intervention did not
significantly affect miR-193b or miR-365a levels (Supplementary
Fig. 7b). Based on RNA-seq data, lincNORS downregulation and
overexpression did not significantly affect the expression of
flanking genes MKL2/MRTFB and PARN, thus indicating a
predominantly trans activity (Supplementary Fig. 8e).
We found that the overall effect of lincNORS on total cellular
cholesterol reflected the changes in transcript abundance. These
were demonstrated in both loss- and gain-of-function studies,
using two cell types (MCF7 and MDA-MB-231) and with two
quantification methods (mass spectrometry and a commercial
kit) (Fig. 4h and Supplementary Fig. 8g). Furthermore, the effect
of lincNORS on cholesterol/lanosterol ratio supports the notion
that it affects predominantly the distal products of the sterol/
steroid biosynthesis than lower molecular weight precursors. The
hydroxylated derivative 25-OH cholesterol did not appear to
change significantly, consistent with the lack of response of the
transcript for the conversion enzyme (Fig. 4i and Supplementary
Fig. 8h).
The impact of lincNORS on cellular phenotypes. Functionally,
the importance of sterol biosynthesis is not restricted to
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hepatocyte physiology, being also essential for steroid hormone
production, as well as for cellular growth and differentiation
programs34. Furthermore, it is intricately connected to steroid
hormone signaling and has been recently recognized as critical for
neoplastic cell escape from steroid hormone dependence35–38.
Given the diverse biological roles of this pathway, we hypothe-
sized that the experimental manipulation of lincNORS would
have consequences on phenotype.
To test this possibility, we examined the effects of lincNORS
upregulation and downregulation in standard assays for cell
viability and invasion under different environmental conditions.
lincNORS knockdown had consistent pro-invasive consequences,
with a probable contribution from deregulated sterol biogenesis, as
suggested by the mitigating effect of simvastatin (Fig. 5a, b and
Supplementary Fig. 10a, b). A similar, although more modest effect
was observed in cell viability assays (Fig. 5c and Supplementary
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Fig. 10c, d). Consistent evidence was observed in MDA-MB-231
xenografts with stably suppressed or overexpressed lincNORS.
Knockdown resulted in increased metastatic load, whereas stable
overexpression had the opposite effect (Fig. 5d, e). However,
lincNORS status in xenografts did not significantly affect primary
tumor size (Supplementary Fig. 10e). The effect of shRNA on
lincNORS expression was still detectable in the harvested tumors,
while miR-193b expression remained unchanged (Fig. 5f). Steroid
biosynthesis transcripts underwent changes similar to those
observed in tissue culture (Fig. 5g).
Mechanistic insights into lincNORS effects. We next investigated
whether lincNORS impacts steroid biosynthesis genes by
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suppressing transcription or by altering mRNA turnover. Following
siRNA-mediated lincNORS knockdown, nascent transcripts were
labeled for 30min with bromouridine (BrU), collected by immu-
noprecipitation with anti-BrU antibody, and quantified by qPCR
analysis. Consistent with a specific posttranscriptional effect, siRNA
treatment lowered total lincNORS transcript, while exhibiting no
significant effect in the BrU-labeled pool (Supplementary Fig. 11a).
We performed similar quantifications for steroid biosynthesis
components and identified significant enrichment in BrU-labeled
transcripts following lincNORS-depletion (Supplementary Fig. 11a).
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In contrast, we did not observe significant changes in transcript
stability, suggesting a predominantly transcriptional impact of
lincNORS (Fig. S11b).
To establish the mechanistic link between lincNORS and sterol
biosynthesis, we searched for protein partners bridging this gap.
To this end, we followed a well-established RNA affinity
purification approach named MS2-TRAP, based on the tagging
of lincNORS by addition of MS2 RNA hairpins39. We collected
complexes binding to MS2-lincNORS or control MS2 RNA in
MCF7 cells and subjected them to mass spectrometry, followed by
a selection of proteins with no binding to the MS2 RNA
(Supplementary Fig. 12a and Supplementary Data 7). Among the
high number of proteins identified, we did not find nuclear
receptors directly or indirectly affecting sterol biogenesis (e.g.,
SREBP1, SREBP2, ESR1, NR5A1), but we observed many
proteins implicated directly or indirectly in controlling gene
expression programs (Supplementary Data 7). However, this data
set, as a whole, was not validated and due to the experimental
caveats of MS2 purification, may contain false positives. The
candidates were further filtered based on several criteria: (1)
documented RNA-binding protein status (RBP); (2) predomi-
nantly nuclear localization; (3) predicted to bind motifs within
lincNORS by RBPmap40; and (4) documented connection to
sterol/steroid pathways. Based on these criteria, we focused on
two members of a known complex: RBP-associated with lethal
yellow mutation (RALY) and its frequent partner heterogeneous
nuclear ribonucleoprotein C (HNRNPC) (Fig. 6a). The former is
of particular interest for multiple reasons: (1) a recent study in
mice by Tontonoz’ group described a role for Raly in the
regulation of cholesterol biosynthesis, in partnership with a
lncRNA termed LeXis41; (2) Nab3, a putative yeast homolog of
Raly has been shown to regulate the ergosterol pathway42,43; (3)
the RALY protein is located in the nucleus, predominantly in the
chromatin-associated fraction, which is the same subcellular
location of lincNORS (Fig. 6b); (4) lastly, lincNORS is present
among the significantly enriched RALY-associated transcripts in
MCF7 cells (under the designation RP11-65J21.3)44. As shown in
Supplementary Fig. 12b, lincNORS is also among the top hypoxia-
responsive lncRNAs bound by RALY.
We confirmed the interaction of endogenous lincNORS with
RALY by RNA immunoprecipitation (RIP) analysis (Fig. 6c). The
importance of RALY for the function of lincNORS was revealed
by loss-of-function experiments. As shown in Fig. 6d, depletion of
RALY using a specific siRNA compromised lincNORS regulatory
effects on steroid biosynthesis genes. Reexamination of RALY
RIP-seq data revealed that RALY interacts significantly with
sterol biosynthesis transcripts (Fig. 6e). Experimentally, we
demonstrated that lincNORS can act as a modifier for some of
these interactions. Specifically, lincNORS depletion measurably
increased the association of RALY with MSMO1 and SQLE
(Fig. 6f). Again, this effect was more prominent at lower oxygen
tension. These results suggest a dynamic interplay between RALY
and the sterol biogenesis program in which lincNORS can act as a
modifying factor. This strategy may reveal additional bona fide
interactors from the candidate list and lead to a more complete
image of lincNORS regulatory actions.
Evidence of lincNORS biological relevance from GWAS.
Although phenotypic associations of naturally occurring genetic
variations can provide uniquely valuable information about gene
function, noncoding loci remain insufficiently interrogated using
this approach. During the past decade, multiple independent
genome-wide association studies (GWAS) have reported highly
significant phenotypic associations for a cluster of single-
nucleotide polymorphisms (SNPs) situated between the MKL2
and PARN loci (Table 1 and Fig. 7a). Although these studies
typically list MKL2 as the name of the locus since it is the closest
coding gene, we provide multiple arguments for lincNORS as the
more plausible functional element.
From a biochemical perspective, most phenotypes listed in
Table 1 are tied to the actions of sex steroids, thus plausibly
affected by a modulator of sterol/steroid biosynthesis expressed
mainly in hormone-responsive tissues45–51. Furthermore, an
examination of the MKL2-PARN genomic region immediately
revealed that these SNPs are more likely to impact MIR193BHG/
lincNORS than MKL2 (or PARN). First, the top GWAS-reported
SNP for puberty onset (rs246185) is very close to the TSS of
lincNORS and overlaps with histone acetylation/methylation
peaks (Fig. 7a). Second, expression quantitative trait loci (eQTL)
analysis in the GTEx database shows that these genetic variations
are correlated with lincNORS, but notMKL2 expression in several
tissues (example shown in Fig. 7b). Colocalization analysis
showed that the GWAS signal for age at menarche and the
eQTL have a high probability of representing the same underlying
signal in skeletal muscle and artery (Supplementary Data 8)52,53.
Finally, based on ARIES mQTL information, these variants also
exhibit significant associations with the methylation of the
MIR193BHG locus rather thanMKL2. Interestingly, these mQTLs
are particularly robust during childhood and adolescence
(Supplementary Fig. 13a), consistent with this locus being
particularly important during a specific developmental stage
(i.e., during childhood).
For a preliminary validation of these variants, we focused on a
1-kb fragment containing rs246185. This segment also contains
Fig. 4 lincNORS modulates cellular sterol homeostasis. a Gene set enrichment analysis of hallmark gene sets associated with lincNORS knockdown versus
the control in MCF-7 (FDR < 0.1). Enrichment plot of cholesterol homeostasis gene set is shown on the right. b Heatmap depicting expression of genes in
the cholesterol synthesis pathway in MCF-7 cells transfected with lincNORS siRNA or siRNA control. The transcriptome was profiled by RNA-seq. A
schematic diagram of the cholesterol synthesis pathway is shown on the right. Differentially expressed genes (FDR < 0.05) are marked with red. c Gene set
enrichment analysis of hallmark gene sets associated with lincNORS knockdown versus the control in MDA-MB-468 (FDR < 0.1). Enrichment plot of
cholesterol homeostasis gene set is shown on the right. d Heatmap depicting expression of genes in the cholesterol synthesis pathway in MDA-MB-468
cells transfected with lincNORS siRNA or siRNA control. The transcriptome was profiled by AmpliSeq. e qPCR analysis of selected cholesterol synthesis
genes in MCF-7 cells transfected with two different lincNORS siRNA. Data represent mean ± SD from three/four biological replicates (*p < 0.05, **p < 0.01,
two-way ANOVA with Dunnett’s test). f qPCR analysis of selected cholesterol synthesis genes in PC-3 cells transfected with two different lincNORS siRNA.
Data represent mean ± SD from three biological replicates (*p < 0.05, **p < 0.01, two-way ANOVA with Dunnett’s test). g qPCR analysis of STARD4 and
SCD expression in MCF-7 and PC-3 cells transfected with two different lincNORS siRNA. Data represent mean ± SD from three biological replicates (*p <
0.05, **p < 0.01, two-way ANOVA with Dunnett’s test). h LC–MS measurement of total cholesterol in MDA-MB-231 cells with stable lincNORS knockdown
or overexpression. Cholesterol reading was normalized to total protein content in each sample. Data represent mean ± SD from three biological replicates
(*p < 0.05, **p < 0.01, ***p < 0.001, two-sided Student’s t-test). i LC–MS metabolite measurement of cholesterol/lanosterol ratio in MDA-MB-231 cells
with stable lincNORS knockdown or overexpression. Data represent mean ± SD from three biological replicates (*p < 0.05, **p < 0.01, ***p < 0.001, two-
sided Student’s t-test).
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rs181766, which is in high linkage disequilibrium with rs246185
and exhibits similarly significant phenotypic associations accord-
ing to the UK Biobank database (Fig. 8a). However, based on
ChIP-seq and open chromatin by Formaldehyde Assisted
Isolation of Regulatory Element (FAIRE-seq) data sets from
ENCODE, rs181766 represents a potentially stronger causal
effector SNP candidate (Supplementary Fig. 13b). Sequences
corresponding to the reference or alternative alleles of rs246185
(T/C) and rs181766 (T/C) were subcloned into pGL4 vectors and
reporter activity was assayed in MCF7 cells. Although the Alt
rs246185 (C) variant had no measurable impact, substitution of
the rs181766-C allele for the T allele had a significant effect on
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reporter activity (Fig. 8b). lincNORS exhibits the only significant
eQTL for rs181766 in GTEx data sets, as described above for the
neighboring GWAS SNPs.
Discussion
Recent noncoding transcriptome studies have revealed new reg-
ulatory mechanisms for lipid metabolism based on lincRNAs
such as LncLSTR, HULC, H19, LeXis, MeXis, and MALAT154.
Our study expands this group with another regulator of the
steroid network program, termed lincNORS.
Understanding how physiological low O2 impacts the home-
ostasis of sterols and steroid derivatives has broad implications on
physiology and disease55–58. Accordingly, knowledge of tissue-
specific modulators, such as lncRNAs, should be particularly
informative. Although highly conserved between primates, the
regions corresponding to the exons and surrounding regulatory
elements of lincNORS exhibit rather limited conservation between
the human and mouse genome. It could be argued therefore that
the relevance of a mouse knockout model for human biology
would be limited. On the other hand, naturally occurring genetic
variations in human populations deliver a consistent message
about this locus. As described above, single-nucleotide variations
close to the TSS of lincNORS are significantly associated with sex
hormone-related phenotypes such as the timing of puberty,
height growth, and genital development. In this study, we map-
ped the GWAS signal to a plausible causal SNP and its target
effector transcript.
How does the insight from GWAS come together in a cohesive
model with lincNORS biochemistry? At this stage, we can only
propose a simplistic scenario, with further details anticipated to
emerge from future studies. For example, the variant of the minor
allele could trigger increased baseline lincNORS expression,
leading to more potent suppression of steroid biosynthesis in
hormonally-responsive tissues and ultimately to a delay in sexual
maturation. Based on the directionality of eQTLs and the nature
of transcriptional regulators (both negative and positive) recrui-
ted in the proximity of rs181766, the causal alternative allele may
exert a positive or negative impact on lincNORS expression,
depending on tissue context.
With the phenotypic connection in mind, it only makes sense
that lincNORS responds to estrogen treatment and that its
genomic neighborhood appears to be a hub for hormone receptor
recruitment. How does hypoxia, the original context that brought
lincNORS to our attention, fit into this context? In recent years
the importance of HIFs and physiologically low O2 for repro-
ductive organ physiology is coming to light from multiple
directions59–62. In summary, one could imagine lincNORS as an
integrator of microenvironmental and hormonal cues that
modulates key aspects of sterol/steroid homeostasis that are
essential for growth and development.
In hindsight, lincNORS’ participation in both low oxygen and
estrogen response should not come as a surprise, as these net-
works are increasingly recognized as interconnected13. Evidence
for a similar dual facet already exists for other hypoxia-inducible
lncRNAs such as NEAT1 and MALAT163,64. In another similarity
to lincNORS, in hypoxic cells, it was previously demonstrated that
NEAT1 and MALAT1 were controlled predominantly by HIF-2,
recruited to distal enhancer elements rather than proximal
promoter6.
Our study may also expand the emerging link between RALY
and sterol/steroid biosynthesis41. It is plausible that the specific
noncoding elements alter the function of RALY-containing
complexes depending on the cellular context. For example, in
hepatocytes in interaction with LeXis RALY becomes relevant for
the “classic” cholesterol biosynthesis. On the other hand, by
partnering with lincNORS in hormonally-responsive tissues
RALY becomes involved in the extrahepatic facets of this path-
way41. As RALY has the potential to regulate gene expression at
multiple steps (positively or negatively), noncoding RNA inter-
actors may be critical for action specificity44,65.
Methods
Cell culture and reagents. Human cancer cell lines MCF-7, MDA-MB-231,
MDA-MB-468, T47D, A549, HT-29, SKOV3, MIA-PaCa2, and U118 were pur-
chased from American Type Culture Collection (ATCC) and maintained at 37 °C
in 5% CO2 with DMEM/High glucose medium supplemented with 10% (v/v) FBS
(Biowest) and antibiotics. All cell lines were routinely tested for mycoplasma
contamination (MycoAlert™ Mycoplasma Detection Kit, Lonza). Long-term
estrogen-deprived (LTED) MCF7 cells were developed as previously described66.
Briefly, MCF7 cells were maintained in medium with 10% dextran-coated charcoal-
stripped FBS (Hyclone Laboratories, Inc., Logan, UT) for 6 months to generate
LTED cells. Renal clear cell carcinoma cells 786-O with empty vector (VHL−) and
786-O with reconstituted VHL (VHL+) were obtained from Dr. Maria Czyzyk-
Krzeska (University of Cincinnati). Patient-derived pancreatic cancer cell lines
Pa03C, Panc10.05, Panc198, as well as cancer-associated fibroblast cell line CAF19,
were obtained from Dr. Anirban Maitra at Johns Hopkins University67. Human
lung fibroblast cell line WI-38 was obtained from Dr. Shadia Jalal’s lab (Indiana
University School of Medicine). Fallopian tube FTE282 epithelial cells (a gift from
Dr. Ronny Drapkin, University of Pennsylvania) were cultured in DMEM-Ham’s
F12 media (Corning) supplemented with 2% Ultroser G (Crescent Chemical
Company) by Dr. Sumegha Mitra. Hypoxia cell culture was performed at 0.2%, 1%,
or 2% O2 for the indicated time in an InVivo200 hypoxia workstation (Ruskin, Inc.,
Cincinnati, OH). Dimethyloxalyglycine (DMOG, Frontier Scientific D1070-100
mg) was dissolved in DMSO and used at 1 mM. Simvastatin (Sigma S6196) was
used at indicated concentrations. Estradiol (Sigma E8875) was dissolved in ethanol
and used at 10 nM. In estradiol experiments, cells were plated and maintained in
medium with 10% dextran-coated charcoal-stripped FBS. Actinomycin D (Sigma
A1410) was used at 2.5 μg/ml.
siRNA transfection. Silencer®Select siRNAs were purchased from ThermoFisher
Scientific and transfected at 10 nM final concentration using RNAiMAX reagent
(Invitrogen, CA) with a reverse transfection protocol. siRNAs used in the study
Fig. 5 lincNORS inhibits cell invasion and metastasis of breast cancer cells. a MDA-MB-231 cells with either knockdown or overexpression of lincNORS
were plated in the Boyden chamber with Matrigel and cultured in 21% O2 or 1% O2. The cells that invaded through Matrigel were quantified 20 h after
plating. Data are shown as mean ± SD from six biological replicates (two-sided Student’s t-test). Representative images (×200 magnified) from three
independent experiments were shown. bMDA-MB-231 cells with stable expression of lincNORS shRNA or control shRNA were plated in a Boyden chamber
with Matrigel in the presence of 1 µM simvastatin or DMSO. The cells that invaded through Matrigel were quantified 20 h after plating. Data are shown as
mean ± SD from three biological replicates (two-sided Student’s t-test). Representative images (×200 magnified) from three independent experiments
were shown. c MDA-MB-231 cells with stable expression of MIR193BHG shRNA or control shRNA were cultured in 1% O2 for 48 h in the presence of
simvastatin or DMSO. Cell viability was measured by MTT assay. Data are shown as mean ± SD from four independent experiments (two-sided Student’s
t-test). d, e Analysis of the metastasis of lincNORS knockdown or overexpressing MDA-MB-231 cells implanted in mice. Representative H&E-stained lung
(d) and liver (e) sections are shown (bars in the upper panel, 3 mm; bars in the lower panel, 200 µm). The percentage of metastatic tumor burden over the
total section area was analyzed using Aperio. Data are plotted as mean ± SD (two-sided Mann–Whitney U test, N= 7). f Expression of HMGCR, HMGCS1,
MVD, SQLE, LSS, and MSMO1 in tumor xenografts generated from MDA-MB-231 cells with stable lincNORS knockdown or control cells was measured by
qPCR. Data were plotted as mean ± SD (two-sided Student’s t-test). g lincNORS and miR193b expressions in the tumor xenografts were measured by qPCR.
Data are plotted as mean ± SD (two-sided Student’s t-test).
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Fig. 6 lincNORS regulates cholesterol synthesis via interaction with RALY. a The level of hnRNPC, RALY, TRIM28, SREBP2, and MS2-GST in the MS2
pulldown material and input lysate was detected by western blot. The data presented are a representative image from two to three independent
experiments. b Subcellular location of RALY was detected by western blot. Tubulin, Lamin-B1, and acetyl-histone H3 were included as controls for
cytoplasmic, nuclear, and chromatin-associated fractions. A representative image from three independent experiments is shown. c RNA
immunoprecipitation (RIP) analysis of RALY. The presence of lincNORS and 18s rRNA in the precipitated complex was detected by qPCR. Data represent
mean ± SD from three biological replicates (two-sided Student’s t-test). d qPCR analysis of NORS, MSMO1, and SQLE expression in MCF-7 cells transfected
with control, lincNORS siRNA, and/or RALY siRNA. Data represent mean ± SD from four biological replicates (two-sided Student’s t-test). RALY knockdown
was confirmed by western blot in each experiment and a representative image is shown on the right. e Enrichment of RNA of cholesterol synthesis genes in
RALY-containing immunoprecipitated complex. The barplot displays the mean fold enrichment ± S.E.M. from three independent RALY RIP-Seq vs control
experiments in MCF7 cells. The statistical significance of the enrichment was determined with CuffDiff v2.2.1 (*FDR < 0.05, **FDR < 0.01, ***FDR < 0.001).
Source data are provided as a Source Data file. f Enrichment of MSMO1, SQLE, H1FX, and GAPDH in RALY-containing immunoprecipitated complex after
lincNORS or hnRNPC knockdown was detected by qPCR. Data represent mean ± SD from four biological replicates (two-sided Student’s t-test).
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include: Silencer®Select negative control siRNA (4390843), FOSL2 siRNAs (Supple-
mentary Data 9), RALY siRNA (s22655), NORS_siRNA_s (5′-GAGCGU-
GUAUAAAACCAAAtt-3′), NORS_siRNA_w (5′-GCAAAGAUGUUUCCAGAGAtt-
3′) and hnRNPC siRNA (5′-CAACGGGACUAUUAUGAUAdTdT-3′).
Stable cell line generation and RACE. The shRNA for lincNORS was designed to
target the sequence 5′-GATTAAAGCAACATGTTATTC-3′. The hairpin template
oligonucleotides were synthesized by Integrated DNA Technologies and subse-
quently cloned into lentiviral vector pLKO.1-puro. The scramble shRNA control
was purchased from Sigma-Aldrich (SHC002). Lentivirus containing shRNA were
generated in 293T cells. MDA-MB-231 and MDA-MB-468 cells were infected with
the lentivirus and selected with 1 µg/mL puromycin (Gibco). All shRNA stable
expressing cell lines were maintained with medium containing 1 µg/mL puromycin
in subsequent cultures. 5′ and 3′ RACE were performed with MCF-7 cells using
FirstChoice RLM-RACE Kit (Ambion) according to the manufacturer’s instruction.
For overexpression, lincNORS was amplified from cDNA using primers: forward:
5′-CGG GAT CCG TCG GCT GCG CGC TCT CTG-3′; reverse: 5′-GCT CTA
GAC TCA ATA AAA TGC TGC TTA TTT ATT-3′ and subsequently cloned into
pcDNA3.1 vector. Cells were transfected with empty vector or lincNORS expressing
construct using Lipofectamine®2000 according to the manufacturer’s instruction
and selected with 1.0 mg/mL G418 (CORNING, 61234RG). The overexpression
stable cell lines were maintained with a medium containing 0.5 mg/mL G418 in
subsequent cultures.
Bioinformatic analyses of public data sets. Data analysis of level 1 TCGA RNA-
seq data was performed under NIH dbGAP approval, Project #5187: “Landscape of
tumor hypoxia in the TCGA data set (P.I. M. Radovich)”. The expression of coding
and noncoding genes was calculated using NGSUtils68. Expression correlation
(Spearman) between lincNORS and each protein-coding gene was calculated using
R (version 3.0.1). Hypoxia score of tumors was calculated using hypoxia metagene
proposed by FM Buffa et al.20 following the method formulated by Maud H.W.
Starmans et al.69. HIF ChIP-Seq data (GSE28352) were used to assess whether HIF
was directly involved in lincNORS induction by hypoxia. Raw data of HIF-1α
ChIP-Seq, HIF-2α ChIP-Seq, and pre-immune ChIP-seq control were downloaded
and aligned to hg19 using Bowtie (version 1.2.1.1). The peaks were visualized in
UCSC genome browser. The other ChIP-Seq data presented in this study were
obtained from ChIP-Altas (http://chip-atlas.org/) and visualized in IGV. Long-
range chromatin interaction in MCF-7 was determined by ChIA-PET data pub-
lished by Li et al. (GSE33664) and visualized in WashU EpiGenome Browser26.
Subcellular fractionation. Subcellular fractionation was performed as described70.
Briefly, cells were pelleted and resuspended in ice-cold HLB buffer (10 mM Tris pH
7.5, 10 mM NaCl, 3 mM MgCl2, 0.3% (v/v) NP-40, 10% (v/v) glycerol) supple-
mented with either RiboLock RNase Inhibitor (Thermo #EO0381) or Halt Protease
Inhibitor (Thermo #78442) for RNA and protein samples respectively. After 10
min incubation on ice, samples were centrifuged at 1000 × g at 4 °C for 3 min and
the supernatant was collected as the cytoplasmic fraction. The remaining pellet was
washed with supplemented HLB buffer three times. Pellet was resuspended in ice-
cold MWS buffer (10 mM Tris–HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea,
and 1% (v/v) NP-40) supplemented with either RNase inhibitor or protease
inhibitor (as above). After 15 min on ice, samples were centrifuged at 1000 × g at 4 °
C for 3 min and the supernatant was collected as the nucleoplasmic fraction. The
remaining pellet, the chromatin-associated fraction, was washed with
supplemented MWS buffer three times. For the RNA samples, 700 µL of QIAzol
was added to resuspend the pellet. For protein samples, 250 µL of NLB buffer
(20 mM Tris (pH 7.5), 150 mM KCl, 3 mM MgCl2, 0.3% (vol/vol) NP-40, and 10%
(vol/vol) glycerol) were added to the pellet, then sonicated three times at 20%
power for 15 s in an ice bath with 2 min of cooling between cycles. After cen-
trifugation, supernatants were collected.
RNAscope. Detection of lincNORS expression and subcellular location in MCF-7
cells with lincNORS-specific RNAscope® probe (designed by Advanced Cell
Diagnostics, ACD) were performed using RNAscope® Multiplex Fluorescent
Reagent kit (ACD 320850) according to the manufacturer’s instructions. A negative
control probe (ACD 322340) was also purchased from ACD. Images were visua-
lized with Olympus BX43 microscope equipped with Olympus U-RFL-T as a
power supply unit.
Invasion assay. Invasion assays were performed in a 24-well plate with BD Falcon
cell culture inserts (Corning 353097) coated with Matrigel (BD Bioscience 356237).
Cells were starved in serum-free medium overnight prior to the experiment. At the
start of the assay, cells were washed with serum-free medium and plated into the
upper chamber at 1 × 105 cells per well in 0.5 mL serum-free DMEM medium.
Complete medium (0.75 mL) with 10% FBS was added to the lower chamber. Cells
were allowed to invade for 20 h under either normoxic or hypoxic conditions. After
incubation, the medium in the upper chamber was aspirated and non-invaded cells
on the upper surface of the filter were removed with a cotton swab. The transwell
membranes were fixed and stained with 0.25% crystal violet in formaldehyde:
methanol (1:9) solution for 30 min. After staining, the membranes were washed
three times with water and air-dried. Invaded cells were visualized using light
microscopy. 150 µL 2% SDS was then added to the membrane, incubated for
20 min to solubilize the crystal violet from stained invaded cells, then transferred to
a new 96-well plate. The relative invasion was determined using absorbance
readings at 550 nm.
Cell viability assay. Cell viability was measured by MTT assay. Cells were plated
in 96-well plates (10,000–20,000 cells per well) and relevant treatment (siRNA
transfection or drug treatment) was performed as described in each experiment. 4 h
prior to the endpoints, 10 µL of MTT (5 mg/mL in PBS, Sigma-Aldrich M5655)
were added to each well containing 100 µL medium and incubated for 4 h. The
medium was aspirated and 100 µL acidic isopropanol (0.04 N HCl in isopropanol)
was added to dissolve the insoluble purple formazan product into a colored
solution. Absorbance was recorded at 570 nm, with a reference at 630 nm serving
as the blank.
RNA extraction and qPCR analysis. For RNA extraction, cells were lysed using
QIAzol Lysis Reagent (QIAGEN) and total RNA was isolated using the RNeasy kit
(QIAGEN) following the manufacturer’s instructions. Reverse transcription was
performed using TaqMan® Reverse Transcription Reagent (Applied Biosystems,
CA) from 1 µg of RNA, and qPCR was performed using gene-specific primers
(Supplementary Data 9) and SYBR green master mix (Applied Biosystem, CA).
18 S rRNA or B2M RNA level was used for normalization. For microRNA analysis,
reverse transcription was performed with TaqMan® MicroRNA Reverse Tran-
scription Kit using 10 ng RNA, and qPCR was performed using TaqMan® Gene
Table 1 Summary of genome-wide association studies reported SNPs in lincNORS promoter.
GWAS
SNP.Id CHR POS_hg38 Distancea MAPPED_TRAIT RISK.ALLELE RAFb p-value Beta Pubmed id Journal
rs1659127 16 14294448 7840 Age at menarche rs1659127-A 0.34 4.00E
−09
2.4c 21102462 Nat Genet
rs1704528 16 14294893 7395 Age at menarche rs1704528-? NR 6.00E−12 −0.033 27182965 Nat Genet
rs246185 16 14301575 713 Age at menarche rs246185-C 0.33 6.80E−16 0.04 25231870 Nature
Tanner puberty stage rs246185-T 0.68 8.88E−09 0.141 24770850 Hum Mol Genet
Age at voice drop rs246185-? NR 7.10E−14 −0.044 27182965 Nat Genet
rs1704529 16 14294769 7519 Androgenetic alopecia rs1704529-C NR 1.42E−09 −0.090334 29146897 Nat Commun
rs246180 16 14298066 4222 Androgenetic alopecia rs246180-? NR 8.00E
−09
0.141 27182965 Nat Genet
rs246185 16 14301575 713 Androgenetic alopecia rs246185-C 0.33 2.65E−10 0.14 28272467 Nat Commun
rs1659127 16 14294448 7840 Body height rs1659127-A 0.48 6.70E−10 0.041 25429064 Hum Mol Genet
Body height rs1659127-A 0.34 1.10E−11 0.027 20881960 Nature
rs246185 16 14301575 713 QT interval rs246185-C 0.34 3.00E−13 0.72 24952745 Nat Genet
aDistance: distance from SNP to lincNORS transcription start site.
bRAF: risk allele frequency.
cPer allele change in age at menarche (weeks).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18411-x
12 NATURE COMMUNICATIONS |         (2020) 11:4755 | https://doi.org/10.1038/s41467-020-18411-x | www.nature.com/naturecommunications
Expression Master Mix. U6 or RNU48 expression was used as an endogenous
control.
Xenograft model. All animal experiments were approved and carried out in
accordance with the Institutional Animal Care and Utilization Committee at
Indiana University School of Medicine. 1 × 106 cells were injected into the mam-
mary fat pad of 10 ~4 weeks old female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)
mice. Tumor growth was monitored twice a week by measurement of the long and
short diameters of the tumor using digital calipers. At the end of the experiments,
animals were killed and the primary tumor, lung, and liver were resected. Lung and
liver tissue were formalin-fixed, paraffin-embedded, sectioned, and stained with
hematoxylin and eosin (H&E) for analysis of metastatic burden. The percentage of
lung or liver tissue containing tumor metastasis was analyzed using Aperio (Leica
Biosystems).
RNA-seq and data analysis. The initial RNA-seq used for identifying hypoxia-
induced lncRNAs was performed on Illumina NextSeq500 platform. Sequenced
reads were mapped to genome with TopHat2 version 2.1.1. Read counts for each
gene were generated with HTSeq-Count from the HTSeq package version 0.6.1p1
and differential expression analysis was carried out using the DESeq2 package
(version 1.12.3) in R/Bioconductor (R version 3.3.1)71. For analysis of lincNORS
function, RNA sequencing was performed using The Ion PI Sequencing 200 Kit v2
Kit (4485149, Life Technologies) on an Ion Proton semiconductor sequencer
according to the kit instructions using the Ion PI Chip Kit v2 (4482321, Life
Technologies). Reads were aligned using STAR (version 2.3.0) and differential
expression was analyzed using the EdgeR (version 3.8.6) package in R (version
3.0.1)72,73. Differential expression with FDR < 0.05 was considered significant.
AmpliSeq and data analysis. Automated library preparation was performed
according to the protocol available with the Ion Chef (MAN0013432) and using the
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Fig. 7 GWAS-reported SNPs in lincNORS promoter support its roles in steroid regulation. a Locations of SNPs in lincNORS promoter reported in NHGRI-
EBI catalog of published genome-wide association studies were visualized in UCSC genome browser. b eQTL boxplot showing genotype-expression
relationships between rs246185, rs246180, rs1704528, and rs1659129 with lincNORS (top) or the closest protein-coding gene MKL2 (bottom) in skeletal
muscle.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18411-x ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4755 | https://doi.org/10.1038/s41467-020-18411-x | www.nature.com/naturecommunications 13
Ion AmpliSeq Kit for Chef DL8 (A29024). Library was further diluted to 50 pM for
sequencing. Template preparation and sequencing were executed using the Ion PI
Hi-Q Chef Kit (A27198, ThermoFisher Scientific) with template quantification
using the IonSphere Quality Control Kit (4468656, ThermoFisher Scientific). The
raw read counts are included in the Supplementary Data 5. Standard workflow for
gene-level expression was conducted using Torrent Suite Version 4.4. The
AmpliSeq Transcriptome Plugin was used to generate standard expression files.
Differential expression was performed in R using the DESeq2 package (version
1.12.3) in R/Bioconductor (R version 3.3.1). Differential expression with FDR <
0.05 was considered significant. Pathway analysis was performed using IPA
and GSEA.
Gene set enrichment analysis. Gene set enrichment analysis was performed
following GSEA User Guide (The Broad Institute)74. Briefly, each condition was
considered as a group and gene list was ranked with GSEA default ranking metrics.
Gene sets from the Molecular Signature Database were used in the analysis to
identify the pathways significantly enriched in each group. Gene sets were per-
mutated 1000 times to obtain empirical FDR corrected p-values.
Western blot analysis. Cell lysates were prepared in RIPA buffer containing
protease inhibitor cocktail (ThermoFisher Scientific). For HIF western blot, cells
were fractionated using RLN buffer (10 mM Tris–HCl pH 8.0, 140 mM NaCl, 1.5
mM MgCl2, 0.5% NP-40, proteinase inhibitor cocktail) and the nuclear fraction
was collected for analysis. Proteins were separated by SDS-polyacrylamide elec-
trophoresis (SDS-PAGE), then transferred onto PVDF membranes (Biorad). Pri-
mary antibodies used in this study included those that recognized HIF-1α (R&D
AF1935), HIF-2α (R&D AF2886; Cell Signaling #7096), β-actin (Thermo MA5-
15739; Santa Cruz sc-1615), β-tubulin (Santa Cruz sc-5274), acetyl-histone H3
(Millipore 06-599), Lamin-B1 (Abcam ab16048), SREBP2 (R&D AF7119),
hnRNPC (Santa Cruz sc-32308), TRIM28 (Abcam ab10483), RALY (Abcam
ab170105), and Enterobacterio Phage MS2 coat protein (Millipore ABE76). For a
complete list of antibodies used please see Supplementary Data 10.
Total cholesterol quantification. Cellular cholesterol was measured using the
Wako Cholesterol assay kit (WAKO, #439-17501) and liquid chromatography-
mass spectrometry. For the measurement using Wako Cholesterol assay kit, cellular
lipids were extracted using 750 µL chloroform: methanol (2:1) solution. After
extraction for 30 min on a rocker, samples were centrifuged for 10 min at 1500 × g
at 4 °C, then the lower chloroform phase was collected and air-dried in a fume
hood until all liquid evaporated. The lipids were resuspended in 10% Triton-X100
in isopropanol. Total cholesterol content was measured using the Wako Choles-
terol assay kit (WAKO, #439-17501) according to the manufacturer’s instructions.
For the measurement using liquid chromatography-mass spectrometry, Oxysterols
were extracted from cells using a modified sterol extraction method from McDo-
nald et al.75. Briefly, cell pellets were extracted with 1 mL of dichloromethane/
methanol 50/50 (v/v) containing 5 µg of butylated hydroxytoluene (BHT) and 200
ng of each deuterated internal standard. 0.2 mL of water were added after mixing
and vortexed for 15 s and centrifuged. The organic layer was transferred to a new
tube and saponified with 0.6 mL of ethanolic KOH (1 N). The tubes were flushed
with nitrogen, capped, and heated to 35 °C for 1 h. 2 mL of water were added and 2
mL dichloromethane. The aqueous fraction was extracted twice with dichlor-
omethane then the two organic fractions were combined and dried with nitrogen
gas at room temperature. The samples were then derivatized according to Honda
et al.76. The derivatization reaction mixture was composed of 100 mg of 2-methyl-
6-nitrobenzoic anhydride, 30 mg of 4-diethylaminopyridine, 80 mg of picolinic
acid, 1.5 mL of tetrahydrofuran (THF). 0.15 mL of this mixture were added to each
sample along with 0.02 mL of triethylamine (TEA). The reaction proceeded at
room temperature for 1 h, then the samples were dried and subsequently recon-
stituted in 0.1 mL of acetonitrile just prior to LC/MS/MS analysis. The analysis was
done with an Agilent 1200 liquid chromatography system coupled to an Agilent
6460 QQQ mass spectrometer (Santa Clara, CA) in Bindley Bioscience Center at
Purdue University. Data were processed using Agilent Masshunter Quantitative
analysis software (V.B.06).
Bromouridine (BrU)-labeled RNA Immunoprecipitation and Bru-Seq. BrU
labeling of newly synthesized RNA and BrU-RNA isolation were performed fol-
lowing the method established by Ljungman’s group22. Briefly, MCF-7 cells
c
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Fig. 8 The impact of rs181766 on lincNORS promoter activity. a List of physical traits that are reported as significantly associated with rs181766 in UK
Biobank (https://genetics.opentargets.org/). b The effect of two selected SNPs rs246185, rs181766 on lincNORS expression was examined using luciferase
assay. A diagram displaying the lincNORS promoter cloning was shown on the right. Data represent mean + SD from 4 to 11 biological replicates (*p < 0.05,
***p < 0.005, one-way ANOVA followed by Dunnett’s multiple comparisons test against REF). c eQTL boxplot showing genotype-expression relationships
between rs181766 and lincNORS (top) or the closest protein-coding gene MKL2 (bottom).
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transfected with either control siRNA or lincNORS siRNA were cultured in hypoxic
conditions. BrU (Sigma-Aldrich 850187) at a final concentration of 2 mM was
added to the plate when cells reached ~80% confluency. After labeling for 30 min,
cells were harvested for total RNA extraction. BrU-labeled RNA was immuno-
precipitated from the total RNA using anti-BrdU antibody (BD Pharmingen,
555627) conjugated with Dynabeads® Goat anti-mouse IgG beads (Invitrogen
#11033). After 1-h incubation, beads were washed three times with 0.1% BSA in
DEPC-PBS to remove unbound RNA then heated at 95 °C for 10 min to recover
the BrU-RNA from the beads. The BrU-RNA and the input RNA were analyzed
using qPCR. The same BrU-RNA isolation procedure was performed with MCF-7
cells cultured in 21% or 1% O2 and the BrU-labeled RNA was sequenced at the
University of Michigan Sequencing Core using Illumina HiSeq2000 sequencer.
MS2-tagged RNA affinity purification. RNA pulldown using MS2-tagged RNA
affinity purification was performed according to the previously described protocol
with slight adaptation77. lincNORS cDNA was cloned into the pMS2 vector
upstream of the MS2 tag. MCF-7 cells were co-transfected with either lincNORS-
MS2 vector or the empty vector and the pMS2-GST vector. 48 h after transfection,
cells were lysed and proteins were quantified. Cell lysate containing 2 mg of protein
was incubated with 60 µL Glutathione sepharose beads (GE Healthcare) for 3 h at 4
°C, followed by five washes with the lysis buffer to remove nonspecific bound
proteins. Beads were further treated with 20 units of RNase-free DNase (QIAGEN)
followed by two washes with NT2 buffer. For western blot analysis, beads were
resuspended in SDS loading buffer, heated up to 95 °C for 5 min, and centrifuged
for 1 min at 14,000 × g. The supernatant was loaded on an SDS-PAGE gel. For
RNA analysis, 700 µL QIAzol lysis buffer were added onto the beads, and RNA was
extracted as previously described. For liquid chromatography-mass spectrometry
(LC–MS) analysis, proteins were recovered from beads and analyzed with the LTQ
Velos Pro ion trap mass spectrometer. RAW files were searched using Proteome
Discoverer 1.4 with SEQUEST HT.
Ribonucleoprotein immunoprecipitation (RIP) analysis. RIP analysis was per-
formed following the protocol outlined by Abcam in Ivan lab. Briefly, nuclear extracts
(native, no crosslink) from MCF-7 cells were prepared in RIPA buffer and 5% of the
lysate was preserved as input RNA control. RALY, TRIM28 antibodies or IgG were
added to the lysate and incubated overnight at 4 °C with gentle rotation. Complexes
were captured using Dynabead Protein A (Life Technologies #10001D) and RNA was
isolated using RNeasy kit (Qiagen). RNA immunoprecipitation performed by Macchi
lab followed the protocol established by Keene et al., with some modifications78.
Briefly, 2 × 107 MCF7 cells were lysed in lysis buffer (10mM HEPES pH 7.4, 100mM
KCl, 5mMMgCl2, 0.5% NP-40, 1mM DTT plus RNase and proteinase inhibitors) for
3 h at −80 °C and centrifuged at 12,000 × g for 30min at 4 °C. The supernatants were
collected and 1% of each sample was set aside as input while the remaining was
incubated for 4 h at 4 °C with protein A magnetic beads (Invitrogen) coated either
with 3 μg of an anti-RALY antibody (Bethyl, A302-069A) or with 3 μg of Rabbit IgG
(Millipore). The beads were then washed four times with NT2 buffer (50mM
Tris–HCl pH 7.5, 150mM NaCl, 1 mMMgCl2, 0.05% NP-40, 1% urea) and RNA was
isolated using TRIzol (Invitrogen). Purified RNA was then converted to cDNA using
the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific), following the
manufacturer’s instructions. The qPCRBIO SyGreen Mix (PCR Biosystems) was used
as a master mix for qRT-PCR. The reactions were performed on a CFX384 thermal
cycler (Biorad) in technical duplicates for each target and for a total of four inde-
pendent biological replicas. RALY RIP-seq data were previously published by Macchi
lab and re-analyzed for lncRNA and cholesterol gene enrichment using the same
method as previously described44.
Luciferase assay. Oligos of lincNORS promoter region containing rs246185 and
rs181766 reference or alternative allele were ordered as gBlocks fragments from
IDT and inserted into pGL4 vectors. MCF7 were seeded at 70–80% confluence in
24-well tissue culture plates 24 h before transfection. Luciferase construct (1 μg)
and pSV-β-galactosidase vector (0.1 μg), or their corresponding empty vector
controls were transfected into cells according to manufacturer’s protocol using
Superfect reagent (Qiagen) with a DNA/Superfect ratio of 1:2.5 (wt/wt). The
promoter activity was calculated from the ratio of firefly luciferase to β-
galactosidase levels and expressed as arbitrary units.
Colocalization analysis. Colocalization analysis was performed to calculate the
likelihood that the same causal SNP drives both lincNORS expression in human
artery and skeletal muscle as well as the age of menarche GWAS signal at this locus.
We queried the GTEx online server (https://www.gtexportal.org) to identify the
tissues in which rs181766 is an eQTL for lincNORS. For each tissue with a linc-
NORS eQTL at rs181766, we used a 500 kb window (±250 kb) around rs181766 to
test whether the eQTL signal colocalized with the age of menarche GWAS signal at
this locus from Day et al.53. Colocalization analysis was performed in R (version
3.4.2) using the “coloc” package52. Data are presented as the posterior probability
of the two signals colocalizing at this locus (PP4) and the posterior probability of
the two signals colocalizing conditioned on there being a signal from both the
eQTL and the GWAS data (PP4/PP3+ PP4). A higher value indicates a higher
likelihood that the signal is shared.
Statistical analysis. Statistical analysis was performed in Excel, R (version 3.0.1,
http:///www.rproject.org/) or GraphPad Prism (version 6). Statistical significance of
differences was determined by unpaired two-sided Student’s t-test or ANOVA with
post hoc comparison where appropriate unless stated otherwise in the figure
legend. The difference was considered statistically significant when p-value was
<0.05. Data are presented as mean ± SD, unless stated otherwise.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
RNA-seq and BrU-seq data that support the findings of this study have been deposited in
the National Center for Biotechnology Information Gene Expression Omnibus (GEO)
and are accessible through the GEO Series accession numbers GSE153293 and
GSE152799, respectively. All other relevant data are available from the corresponding
author upon reasonable request. Source data are provided with this paper.
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